Lexaria Enters New Global Exclusive Collaboration And License Agreement With SulfoSyn; Global Exclusivity For All Non-Pharmaceutical Applications Of DehydraTECH-Sulforaphane Has Been Awarded
Portfolio Pulse from Happy Mohamed
Lexaria Bioscience Corp. (NASDAQ:LEXX) has granted a new global, exclusive license to use DehydraTECH technology to SulfoSyn Limited. The license is for all non-pharmaceutical uses of sulforaphane world-wide. Lexaria is also being contracted to perform certain DehydraTECH-related manufacturing operations at its US partner facility on behalf of SulfoSyn for an initial term of 2 years.
October 13, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexaria Bioscience Corp. has entered into a new global exclusive collaboration and license agreement with SulfoSyn. This could potentially increase Lexaria's revenues.
The new global exclusive collaboration and license agreement with SulfoSyn could potentially increase Lexaria's revenues. Lexaria is also being contracted to perform certain DehydraTECH-related manufacturing operations at its US partner facility on behalf of SulfoSyn for an initial term of 2 years, which could further increase its revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100